Finerenone
Based on 11 publication(s) in Google Scholar
Finerenone (BAY 94-8862) is a third-generation, selective, and orally active nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50 = 18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (> 500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease.
For research use only. We do not sell to patients.
- Purity : 99.91%
- CAS No.: 1050477-31-0
- Formula: C21H22N4O3
- Molecular Weight:378.42
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-B0251
EplerenoneAldosterone Blocker -
HY-10450
DapagliflozinSGLT2 Inhibitor -
HY-114118
SemaglutideGLP-1R Agonist -
HY-16774
VericiguatsCG Stimulator -
HY-Y1891
Tween 80 -
HY-10162
OlaparibPARP Inhibitor -
HY-Y0873
PEG300Neutral Polymer -
HY-15409
EmpagliflozinSGLT2 Inhibitor -
HY-113313
AldosteroneMineralocorticoid Steroid -
HY-B0561
SpironolactoneAldosterone/Corticoid Receptor/Androgen Antagonists -
HY-100471
EsaxerenoneMineralocorticoid Antagonist -
HY-10219
RapamycinmTOR Inhibitor
Publications Citing Use of MedChemExpress (MCE) Finerenone
More- Nature. 2023 Feb;614(7947):326-333. [Abstract]
- Science. 2026 Feb 5;391(6785):eadz4075. [Abstract]
- Redox Biol. 2023 Dec:68:102946. [Abstract]
- Phytomedicine. 2025 Apr:139:156473. [Abstract]
- Biochem Pharmacol. 2026 Aug 18;254(Pt 1):118370.
- Biochem Pharmacol. 2026 Mar:245:117630. [Abstract]
- Sci Rep. 2026 Jun 12. [Abstract]
- Diabetol Metab Syndr. 2024 Nov 24;16(1):283. [Abstract]
- Mol Cell Endocrinol. 2026 Oct:620:112845. [Abstract]
- Gene Rep. 2025 Oct 4.
- bioRxiv. 2026 Sep 11.
Customer Validation & Images
-
In Vivo Efficacy Study
-
RT-PCR
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO-K1 | IC50 |
16 nM
Compound: 3
|
Antagonist activity against human mineralocorticoid receptor expressed in CHOK1 cells after 10 to 30 mins by luciferase reporter gene assay
Antagonist activity against human mineralocorticoid receptor expressed in CHOK1 cells after 10 to 30 mins by luciferase reporter gene assay
|
[PMID: 22866979] |
| HEK-293T | IC50 |
58 nM
Compound: S-1p
|
Antagonist activity at Gal4-fused human MR LBD expressed in HEK293T cells assessed as inhibition of aldosterone-induced transactivation activity after 16 hrs by luciferase reporter gene assay
Antagonist activity at Gal4-fused human MR LBD expressed in HEK293T cells assessed as inhibition of aldosterone-induced transactivation activity after 16 hrs by luciferase reporter gene assay
|
[PMID: 28051871] |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Twelve-week-old MWF rat[1]
-
Dosage:10 mg/kg
-
Administration:P.o.; daily for 4 weeks
-
Result:Significantly reduced SBP in MWF rats; led to a significant reduction (>40%) in albuminuria in the MWF model.
-
Animal Model:Twelve-week-old MWF rat[1]
-
Dosage:10 mg/kg
-
Administration:P.o.; daily for 4 weeks
-
Result:Significantly reduced SBP in MWF rats; led to a significant reduction (>40%) in albuminuria in the MWF model.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1050477-31-0
-
Appearance Solid
-
Molecular Weight 378.42
-
Formula C21H22N4O3
-
Color White to off-white
-
SMILES
O=C(C1=C(C)NC2=C(C(OCC)=NC=C2C)[C@@H]1C3=CC=C(C#N)C=C3OC)N
-
Synonyms
BAY 94-8862
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Nature
2023 Feb;614(7947):326-333. PMID: 36599367
Finerenone purchased from MedChemExpress. Usage Cited in: Nature. 2023 Feb;614(7947):326-333. [Abstract]
Finerenone (1 μM; 24 h) increases Il6, Il1b, and Ccl2 gene expression in primary mouse astrocytes activated in vitro with 1 ng/mL of IL-1β and TNFα, and (1 μM; 4 h) also boosts Xbp1 splicing.
-
Science
2026 Feb 5;391(6785):eadz4075. PMID: 41643022 -
Redox Biol
Non-steroidal mineralocorticoid receptor antagonist finerenone ameliorates mitochondrial dysfunction via PI3K/Akt/eNOS signaling pathway in diabetic tubulopathy. [Abstract]2023 Dec:68:102946. PMID: 37924663
Finerenone purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Dec:68:102946. [Abstract]
Effect of Finerenone (3 mg/kg/d; p.o.for 12 weeks) on kidney morphology alterations in HFD/STZ-induced T2DM mice's kidneys.
Finerenone purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Dec:68:102946. [Abstract]
Effect of Finerenone (3 mg/kg/d; p.o.for 12 weeks) on serum creatinine and urinary ACR alterations in HFD/STZ-induced T2DM mice's kidneys.
Finerenone purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Dec:68:102946. [Abstract]
PAS staining provides representative histology of the renal cortex after Finerenone (3 mg/kg/d; p.o.for 12 weeks) treatment in HFD/STZ-induced T2DM mice's kidneys.
Finerenone purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Dec:68:102946. [Abstract]
Finerenone (5 mM; 24 h) alleviates the overactivation of MR via PI3K/Akt/eNOS signaling pathway in HK-2 cells treated with HG.
Finerenone purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Dec:68:102946. [Abstract]
Effect of Finerenone (5 mM; 24 h) on dysfunctional mitochondria, mitoROS generation, and HK-2 cell apoptosis.
-
Phytomedicine
Baicalin alleviates lipid metabolism disorders in diabetic kidney disease via targeting FKBP51. [Abstract]2025 Apr:139:156473. PMID: 39986224
Finerenone purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Apr:139:156473. [Abstract]
Finerenone (10 mg/kg; p.o. daily from the fifth week) protects against low body weight in diabetic kidney disease mice.
-
-
Biochem Pharmacol
Cichoriin suppresses hepatic lipid accumulation and fibrosis in mice metabolic dysfunction associated steatohepatitis via the AMPK pathway. [Abstract]2026 Mar:245:117630. PMID: 41386558 -
Sci Rep
Finerenone attenuates myocardial injury and enhances vascular repair via regulation of autophagy, apoptosis, and angiogenesis. [Abstract]2026 Jun 12. PMID: 42285992 -
Diabetol Metab Syndr
Finerenone attenuates downregulation of the kidney GLP-1 receptor and glucagon receptor and cardiac GIP receptor in mice with comorbid diabetes. [Abstract]2024 Nov 24;16(1):283. PMID: 39582036 -
Mol Cell Endocrinol
The mineralocorticoid receptor and its antagonist finerenone regulate hepatic lipid accumulation via the AMPK/SREBP1/FASN signaling. [Abstract]2026 Oct:620:112845. PMID: 42264075 -
-
Solvent & Solubility
In Vitro:
DMSO : 70 mg/mL (184.98 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.93 mg/mL (5.10 mM); Clear solution
This protocol yields a clear solution of ≥ 1.93 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (19.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.93 mg/mL (5.10 mM); Clear solution
This protocol yields a clear solution of ≥ 1.93 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (19.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Bärfacker L, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7(8):1385-1403. [Content Brief]
[2]. González-Blázquez R, et al. Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress. Front Pharmacol. 2018;9:1131. Published 2018 Oct 9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6426 mL | 13.2128 mL | 26.4257 mL | 66.0642 mL |
| 5 mM | 0.5285 mL | 2.6426 mL | 5.2851 mL | 13.2128 mL | |
| 10 mM | 0.2643 mL | 1.3213 mL | 2.6426 mL | 6.6064 mL | |
| 15 mM | 0.1762 mL | 0.8809 mL | 1.7617 mL | 4.4043 mL | |
| 20 mM | 0.1321 mL | 0.6606 mL | 1.3213 mL | 3.3032 mL | |
| 25 mM | 0.1057 mL | 0.5285 mL | 1.0570 mL | 2.6426 mL | |
| 30 mM | 0.0881 mL | 0.4404 mL | 0.8809 mL | 2.2021 mL | |
| 40 mM | 0.0661 mL | 0.3303 mL | 0.6606 mL | 1.6516 mL | |
| 50 mM | 0.0529 mL | 0.2643 mL | 0.5285 mL | 1.3213 mL | |
| 60 mM | 0.0440 mL | 0.2202 mL | 0.4404 mL | 1.1011 mL | |
| 80 mM | 0.0330 mL | 0.1652 mL | 0.3303 mL | 0.8258 mL | |
| 100 mM | 0.0264 mL | 0.1321 mL | 0.2643 mL | 0.6606 mL |
Finerenone Related Classifications
HY-111372 Related Classifications
Powered by Bioz